Tong Ren Tang Technologies Renews Procurement, Sale Deals With Controlling Shareholder

MT Newswires Live

Sep 30

Beijing Tong Ren Tang's (SHA:600085) subsidiary, Tong Ren Tang Technologies (HKG:1666), renewed two agreements with the company's controlling shareholder, China Beijing Tong Ren Tang (Group), for two more years, according to a Shanghai bourse filing on Tuesday.

The deal includes Tong Ren Tang Technologies' procurement of Chinese medicine raw materials and the sale of products between 2026 and 2028.

The procurement is estimated to cap at 45.5 million yuan between January and August and the sales at 57.7 million yuan in the same period, the Chinese pharmaceutical company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2571108394"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571108394\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571108394?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 12:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571108394","market":"sh","top_or_hot":-1,"title":"Tong Ren Tang Technologies Renews Procurement, Sale Deals With Controlling Shareholder","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/600085\">Beijing Tong Ren Tang</a>'s (SHA:600085) subsidiary, <a href=\"https://laohu8.com/S/TGRNF\">Tong Ren Tang Technologies</a> (HKG:1666), renewed two agreements with the company's controlling shareholder, China Beijing <a href=\"https://laohu8.com/S/01666\">Tong Ren Tang</a> (Group), for two more years, according to a Shanghai bourse filing on Tuesday.</p><p>The deal includes Tong Ren Tang Technologies' procurement of Chinese medicine raw materials and the sale of products between 2026 and 2028.</p><p>The procurement is estimated to cap at 45.5 million yuan between January and August and the sales at 57.7 million yuan in the same period, the Chinese pharmaceutical company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tong Ren Tang Technologies Renews Procurement, Sale Deals With Controlling Shareholder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTong Ren Tang Technologies Renews Procurement, Sale Deals With Controlling Shareholder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-30 12:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/600085\">Beijing Tong Ren Tang</a>'s (SHA:600085) subsidiary, <a href=\"https://laohu8.com/S/TGRNF\">Tong Ren Tang Technologies</a> (HKG:1666), renewed two agreements with the company's controlling shareholder, China Beijing <a href=\"https://laohu8.com/S/01666\">Tong Ren Tang</a> (Group), for two more years, according to a Shanghai bourse filing on Tuesday.</p><p>The deal includes Tong Ren Tang Technologies' procurement of Chinese medicine raw materials and the sale of products between 2026 and 2028.</p><p>The procurement is estimated to cap at 45.5 million yuan between January and August and the sales at 57.7 million yuan in the same period, the Chinese pharmaceutical company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGRNF","symbol_name":"Tong Ren Tang Technologies","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2571108394","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571108394","pubTimestamp":1759205114,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Beijing Tong Ren Tang's  subsidiary, Tong Ren Tang Technologies , renewed two agreements with the company's controlling shareholder, China Beijing Tong Ren Tang , for two more years, according to a Shanghai bourse filing on Tuesday.The deal includes Tong Ren Tang Technologies' procurement of Chinese medicine raw materials and the sale of products between 2026 and 2028.The procurement is estimated to cap at 45.5 million yuan between January and August and the sales at 57.7 million yuan in the same period, the Chinese pharmaceutical company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600085":"同仁堂","TGRNF":"Tong Ren Tang Technologies","LU1688375341.USD":"贝莱德中国灵活股票基金","01666":"同仁堂科技","BK4007":"制药","BK0097":"医药电商","BK0028":"国家队","BK0239":"医药制造","BK0113":"养老产业","BK1583":"高瓴概念","BK0086":"举牌","BK0183":"MSCI概念","BK0188":"融资融券","BK1191":"制药","BK1515":"抗疫概念","BK1606":"中医药概念","BK0012":"证金概念","BK0196":"行业龙头"},"translate_title":"同仁堂科技与控股股东续签采购、销售协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600085":0.9,"01666":1,"TGRNF":1.5},"content_text":"Beijing Tong Ren Tang's (SHA:600085) subsidiary, Tong Ren Tang Technologies (HKG:1666), renewed two agreements with the company's controlling shareholder, China Beijing Tong Ren Tang (Group), for two more years, according to a Shanghai bourse filing on Tuesday.The deal includes Tong Ren Tang Technologies' procurement of Chinese medicine raw materials and the sale of products between 2026 and 2028.The procurement is estimated to cap at 45.5 million yuan between January and August and the sales at 57.7 million yuan in the same period, the Chinese pharmaceutical company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}